News
It doesn't always feel like it, but make no mistake, this is what winning looks like
1+ hour, 55+ min ago (158+ words) PharmaDispatch It doesn't always feel like it, but make no mistake, this is what winning looks like Our health technology assessment institution is not into unconditional surrenders. It habitually buys time to consolidate its position with the goal of revisiting…...
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
1+ hour, 50+ min ago (136+ words) PharmaDispatch Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne Australian company Telix Pharmaceuticals has opened a major facility in North Melbourne that brings radiochemistry laboratories, clinical product manufacturing, patient dose administration and imaging together under one roof. … Minister recommits…...
A single payer system in which the worst kind of inequity is the only one permitted
1+ day, 1+ hour ago (153+ words) PharmaDispatch A single payer system in which the worst kind of inequity is the only one permitted We can pay for private insurance to ensure choice and timely access to a hospital surgery, but not prescription medicines. How does that…...
An opportunity to become a global destination for paediatric oncology trials
2+ day, 1+ hour ago (158+ words) PharmaDispatch An opportunity to become a global destination for paediatric oncology trials Thirteen representatives from government, industry, clinical care, research and patient advocacy met to identify practical actions to strengthen Australia’s paediatric oncology clinical trial ecosystem and attract greater investment…...
Australian partnership advances gene therapy for Retinitis Pigmentosa
2+ day, 1+ hour ago (147+ words) PharmaDispatch Australian partnership advances gene therapy for Retinitis Pigmentosa Sydney-based Viral Vector Manufacturing Facility and Melbourne-headquartered Mirugen have signed a non-exclusive Letter of Intent to evaluate and potentially develop the company's AAV-based gene therapy candidate targeting Retinitis Pigmentosa. … What is…...
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
2+ day, 1+ hour ago (150+ words) PharmaDispatch Minister recommits to keeping MS medicines on the PBS while awaiting formal advice The minister's reference to the US and broader international pressures belies the reality that the situation currently confronting MS patients relates to the demanded price reduction…...
Widening inequality threatens outcomes for Australians with neuroendocrine cancer
2+ day, 1+ hour ago (158+ words) PharmaDispatch Widening inequality threatens outcomes for Australians with neuroendocrine cancer “This isn't simply a cancer story. It's an equity story,” said Meredith Cummins, CEO of NeuroEndocrine Cancer Australia. “Where you live, how far you are from specialist care, and your…...
Budget outlook now hangs on disability savings, but what about pharmaceuticals
2+ day, 1+ hour ago (150+ words) PharmaDispatch Budget outlook now hangs on disability savings, but what about pharmaceuticals The Parliamentary Budget Office’s 2026–27 Medium‑Term Budget Outlook paints a cautious picture for health, disability and medicines spending, with doubts over the budgeted savings for the National Disability…...
Can GLP-1s be more transformative than AI - one person believes they already are - BioPharmaDispatch
3+ day, 2+ hour ago (154+ words) Can GLP-1s be more transformative than AI - one person believes they already are PharmaDispatch Can GLP-1s be more transformative than AI - one person believes they already are While Australia is debating whether to fund weight-loss medication for a group of…...
What is it with this organisation's obsession with pharmacy and Europe?
4+ day, 1+ hour ago (131+ words) PharmaDispatch What is it with this organisation's obsession with pharmacy and Europe? This report is an out-of-touch, selectively sourced exercise in policy obsession, with Europe of all places, that ignores the one place where pharmacy supermarkets are common and the…...